ADMA Biologics, Inc.
ADMA Biologics, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2004, the company has established itself as a leader in the development and commercialisation of specialty biologics, particularly in the field of immunoglobulin therapies. ADMA focuses on providing innovative solutions for patients with immune deficiencies and other serious conditions, offering unique products such as its proprietary immunoglobulin, ASCENIV. This product stands out due to its high purity and specific formulation, catering to the needs of patients requiring immunotherapy. With a strong market position, ADMA Biologics has achieved significant milestones, including FDA approvals and partnerships that enhance its operational reach across North America. The company continues to drive advancements in the biologics sector, committed to improving patient outcomes through its specialised therapies.
DitchCarbon Score
How does ADMA Biologics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ADMA Biologics, Inc.'s score of 25 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
ADMA Biologics, Inc.'s reported carbon emissions
ADMA Biologics, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Consequently, there are no documented reduction targets or climate pledges associated with the company at this time. As a result, ADMA Biologics, Inc. does not inherit any emissions data from a parent or related organization, nor does it have any commitments to the Science Based Targets initiative (SBTi) or other climate initiatives. The company’s current climate strategy and commitments remain unspecified, reflecting a broader context in which many organisations are increasingly focusing on sustainability and emissions reduction. In summary, while ADMA Biologics, Inc. has not disclosed specific emissions data or reduction initiatives, the industry trend towards climate accountability suggests that future commitments may be forthcoming.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
ADMA Biologics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
